Skip to content

Yew Bio-Pharm Group, Inc.: filings

Every Yew Bio-Pharm Group, Inc. annual and quarterly report in the SEC record with the published financial measures it tagged, 39 filings, each linked to its SEC index.

Filing record ends 2021-11-15

The latest filing in this captured record is a 10-Q filed 2021-11-15. No later filing is in the SEC companyfacts record captured on 2026-09-22. Yew Bio-Pharm Group, Inc. may have stopped filing, merged, or changed its reporting entity; nothing on this page describes its current status. Values are as reported at the time.

Filings with published measures

Each page shows what one filing reported, as tagged in that filing, with the periods it covered. Later filings can restate a value; the company overview shows the latest-filed value per period.

FormFiledFiscal periodMeasuresFactsSEC accession
10-Q2021-11-15fiscal Q3 2021411060001493152-21-028337
10-Q2021-08-16fiscal Q2 2021431180001493152-21-020137
10-Q2021-05-17fiscal Q1 202142860001493152-21-011687
10-K2021-03-30fiscal FY 202049980001493152-21-007242
10-Q2020-11-13fiscal Q3 2020431210001493152-20-021299
10-Q2020-08-14fiscal Q2 2020421150001213900-20-022258
10-Q2020-06-29fiscal Q1 202042870001213900-20-016138
10-K2020-05-14fiscal FY 201949970001213900-20-012320
10-Q2019-11-14fiscal Q3 2019451300001213900-19-023461
10-Q2019-08-13fiscal Q2 2019441200001213900-19-015543
10-Q2019-05-22fiscal Q1 201942820001213900-19-009396
10-K2019-05-07fiscal FY 201845900001213900-19-007971
10-Q2018-11-19fiscal Q3 2018401120001213900-18-016179
10-Q2018-08-14fiscal Q2 2018401130001213900-18-010991
10-Q2018-05-15fiscal Q1 201835740001213900-18-006319
10-K2018-04-02fiscal FY 201744900001213900-18-003854
10-Q2017-11-13fiscal Q3 2017381070001213900-17-011844
10-Q2017-08-14fiscal Q2 2017411130001213900-17-008642
10-Q2017-05-15fiscal Q1 201739770001213900-17-005222
10-K2017-03-31fiscal FY 201645910001213900-17-003143
10-Q2016-11-14fiscal Q3 2016411120001213900-16-018438
10-Q2016-08-15fiscal Q2 2016401110001213900-16-015900
10-Q2016-05-16fiscal Q1 201641800001213900-16-013438
10-K2016-03-30fiscal FY 201542840001213900-16-012043
10-Q2015-11-16fiscal Q3 2015391080001213900-15-008636
10-Q2015-08-18fiscal Q2 2015391070001213900-15-006290
10-Q2015-05-14fiscal Q1 201539750001213900-15-003652
10-K2015-03-31fiscal FY 201441820001213900-15-002328
10-Q2014-11-17fiscal Q3 2014391070001213900-14-008299
10-Q2014-08-14fiscal Q2 2014381050001213900-14-005827
10-Q2014-05-20fiscal Q1 201436710001213900-14-003625
10-K2014-03-31fiscal FY 201341810001213900-14-001859
10-Q2013-11-12fiscal Q3 2013381070001213900-13-006197
10-Q2013-08-14fiscal Q2 2013381070001213900-13-004261
10-Q2013-05-14fiscal Q1 201336720001213900-13-002438
10-K2013-04-11fiscal FY 201241810001213900-13-001732
10-Q2012-11-13fiscal Q3 2012411130001213900-12-006032
10-Q/A2012-09-14fiscal Q2 2012411130001213900-12-005281
10-Q/A2012-09-13fiscal Q2 2012411130001213900-12-005260

Inspect the source

Entity
Yew Bio-Pharm Group, Inc. / CIK 0001548240
Captured
SEC response SHA-256
42d239bf62595328b4b0f26c5a40397396731e01ab6dfcaf5b29c1b41870e6be

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001548240.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))